{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:52:35Z","timestamp":1776703955172,"version":"3.51.2"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.02.020","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T09:14:36Z","timestamp":1614417276000},"page":"367-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study"],"prefix":"10.1016","volume":"161","author":[{"given":"L.","family":"Bernard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.N.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sinasac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Reade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.02.020_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0010","unstructured":"Trends in the Incidence and Mortality of Female Reproductive System Cancers. https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-624-x\/2015001\/article\/14095-eng.htm. (Accessed April 9, 2020) 2015."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.canep.2013.03.008","article-title":"Recent changes in endometrial cancer trends among menopausal-age US women","volume":"37","author":"Wartko","year":"2013","journal-title":"Cancer Epidemiol."},{"issue":"35","key":"10.1016\/j.ygyno.2021.02.020_bb0020","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the role of obesity in endometrial cancer risk, prevention, and treatment","volume":"34","author":"Onstad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.020_bb0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cdp.2008.08.004","article-title":"Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers","volume":"32","author":"Polednak","year":"2008","journal-title":"Cancer Detect. Prev."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.020_bb0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ijc.24803","article-title":"Incident cancer burden attributable to excess body mass index in 30 European countries","volume":"126","author":"Renehan","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"9612","key":"10.1016\/j.ygyno.2021.02.020_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet."},{"issue":"7630","key":"10.1016\/j.ygyno.2021.02.020_bb0040","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/bmj.39367.495995.AE","article-title":"Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study","volume":"335","author":"Reeves","year":"2007","journal-title":"Br. Med. J."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1055-9965.EPI-07-2567","article-title":"Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype","volume":"17","author":"McCullough","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"12","key":"10.1016\/j.ygyno.2021.02.020_bb0050","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/1055-9965.EPI-10-0832","article-title":"Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis","volume":"19","author":"Crosbie","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2009.03.039","article-title":"Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship","volume":"114","author":"Fader","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.020_bb0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1471-0528.13717","article-title":"Modelling body mass index and endometrial cancer risk in a pooled-analysis of three case-control studies","volume":"123","author":"Rota","year":"2016","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"issue":"16","key":"10.1016\/j.ygyno.2021.02.020_bb0065","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2217\/fon.14.192","article-title":"USA endometrial cancer projections to 2030: should we be concerned?","volume":"10","author":"Sheikh","year":"2014","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.020_bb0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jnci\/djs530","article-title":"Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients","volume":"105","author":"Arem","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.020_bb0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1200\/JCO.2016.70.5822","article-title":"Intentional weight loss and endometrial cancer risk","volume":"35","author":"Luo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.020_bb0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2017.02.036","article-title":"Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study","volume":"145","author":"Anveden","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.11.012","article-title":"Bariatric surgery decreases the risk of uterine malignancy","volume":"133","author":"Ward","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.020_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029473","article-title":"Acceptability and feasibility of weight management programmes for adults with severe obesity: a qualitative systematic review","volume":"9","author":"Skea","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0095","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12885-018-4334-5","article-title":"Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis","volume":"18","author":"Chu","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2017.10.026","article-title":"Aspirin use and endometrial cancer risk and survival","volume":"148","author":"Takiuchi","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1 I","key":"10.1016\/j.ygyno.2021.02.020_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9378(00)70486-8","article-title":"Risk factors among young women with endometrial cancer: A danish case- control study","volume":"182","author":"Parslov","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.020_bb0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.2910540214","article-title":"Oral contraceptives and endometrial cancer: Do other risk factors modify the association?","volume":"54","author":"Stanford","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.020_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bjc.6603260","article-title":"Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004","volume":"95","author":"Vessey","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/AOG.0b013e31817d53a4","article-title":"Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women","volume":"112","author":"Kwon","year":"2008","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.02.020_bb0130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/jech.52.12.775","article-title":"Combined oral contraceptives, smoking, and cardiovascular risk","volume":"52","author":"Farley","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2, PART 1","key":"10.1016\/j.ygyno.2021.02.020_bb0140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0145","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/AOG.0000000000001616","article-title":"Levonorgestrel intrauterine device as an endometrial cancer prevention strategy in obese women","volume":"128","author":"Dottino","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1377\/hlthaff.2018.05144","article-title":"It\u2019s still the prices, stupid: why the US spends so much on health care, and a tribute to UWE Reinhardt","volume":"38","author":"Anderson","year":"2019","journal-title":"Health Aff."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.contraception.2016.02.024","article-title":"Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A","volume":"93","author":"Rowe","year":"2016","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.contraception.2014.02.011","article-title":"Extended use of the intrauterine device: a literature review and recommendations for clinical practice","volume":"89","author":"Wu","year":"2014","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.contraception.2012.01.015","article-title":"Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system","volume":"86","author":"Seeber","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0170","author":"Surveillance Research Program"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0175","article-title":"Canadian cancer statistics 2018","author":"Canadian Cancer Statistics Advisory Committee","year":"2018","journal-title":"Can. Cancer Soc."},{"key":"10.1016\/j.ygyno.2021.02.020_bb0180","series-title":"An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]","author":"Garrison","year":"2018"},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.020_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.02.020_bb0190","article-title":"Is the choice of cost-effectiveness threshold in cost-utility analysis endogenous to the resulting value of technology? A systematic review","author":"Padula","year":"2020","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0195","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada 4th Edition Appendix-Worked Example Service Line: CADTH Methods and Guidelines CADTH METHODS AND GUIDELINES","year":"2017"},{"issue":"15","key":"10.1016\/j.ygyno.2021.02.020_bb0200","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in Health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ygyno.2021.02.020_bb0205","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","article-title":"Dealing with time in Health economic evaluation: methodological issues and recommendations for practice","volume":"33","author":"O\u2019Mahony","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00019053-200523060-00001","article-title":"Incorporation of uncertainty in health economic modelling studies","volume":"23","author":"O\u2019Hagan","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0215","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0225","author":"Statistics Canada"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0230","author":"Statistics Canada"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0235","author":"Statistics Canada"},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.020_bb0240","first-page":"95","article-title":"Estimating the cost of cancer care in British Columbia and Ontario: a Canadian inter-provincial comparison","volume":"12","author":"De Oliveira","year":"2017","journal-title":"Healthc Policy"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0250","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1191\/0962280202sm304ra","article-title":"Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods","volume":"11","author":"O\u2019Brien","year":"2002","journal-title":"Stat. Methods Med. Res."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.020_bb0255","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/13697137.2017.1358921","article-title":"Abnormal uterine bleeding in perimenopause","volume":"20","author":"Goldstein","year":"2017","journal-title":"Climacteric."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0260","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10552-006-0113-8","article-title":"Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition","volume":"18","author":"Friedenreich","year":"2007","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.ygyno.2021.02.020_bb0265","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.puhe.2015.04.017","article-title":"The effect of body mass index on endometrial cancer: a meta-analysis","volume":"129","author":"Jenabi","year":"2015","journal-title":"Public Health"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ije\/dyi226","article-title":"Weight change and risk of endometrial cancer","volume":"35","author":"Trentham-Dietz","year":"2006","journal-title":"Int. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0275","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2006.10.045","article-title":"Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study","volume":"105","author":"MODESITT","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.02.020_bb0280","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/cncr.22351","article-title":"Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma","volume":"107","author":"von Gruenigen","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.020_bb0285","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2015.12.010","article-title":"Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer","volume":"140","author":"Cholakian","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.020_bb0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF02108593","article-title":"The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH - a study of 17 patients under treatment for endometrial cancer","volume":"230","author":"Leis","year":"1980","journal-title":"Arch. Gynecol."},{"key":"10.1016\/j.ygyno.2021.02.020_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.12.273","article-title":"Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy","author":"Mandelbaum","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0300","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2265.1982.tb01625.x","article-title":"Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD","volume":"17","author":"Nilsson","year":"1982","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.020_bb0305","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.contraception.2019.01.003","article-title":"Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index","volume":"99","author":"Natavio","year":"2019","journal-title":"Contraception."},{"key":"10.1016\/j.ygyno.2021.02.020_bb0310","author":"FSRH"},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.020_bb0315","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/ijc.22081","article-title":"Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China","volume":"119","author":"Tao","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.020_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.07.037","article-title":"Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis","volume":"203","author":"Gallos","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.020_bb0325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/09513590.2016.1153056","article-title":"Why perimenopausal women should consider to use a levonorgestrel intrauterine system","volume":"32","author":"Wildemeersch","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ygyno.2021.02.020_bb0330","series-title":"Cost effectiveness in health and medicine","author":"Neumann","year":"2017"},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.020_bb0335","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ijo.2012.94","article-title":"Obesity and endometrial cancer survival: a systematic review","volume":"37","author":"Arem","year":"2013","journal-title":"Int. J. Obes."},{"issue":"18","key":"10.1016\/j.ygyno.2021.02.020_bb0340","first-page":"1","article-title":"Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: a Health technology assessment","volume":"16","author":"Health Quality Ontario","year":"2016","journal-title":"Ont. Health Technol. Assess. Ser."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.020_bb0345","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.contraception.2015.01.007","article-title":"Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices","volume":"91","author":"Heinemann","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.ygyno.2021.02.020_bb0350","author":"Patient Cost Estimator"},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.020_bb0355","first-page":"369","article-title":"Levonorgestrel intrauterine device use in overweight and obese women","volume":"74","author":"Saito-Tom","year":"2015","journal-title":"Hawaii J. Med. Public Health"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:47:40Z","timestamp":1715820460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090825821001657"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}